Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2019-10-23 Major Shareholding Noti…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification
2019-10-23 English
Regulatory Filings 2019
Regulatory Filings
2019-10-22 English
424B4
Prospectus
2019-10-18 English
Innate Pharma annonce l’exercice intégral de l’option de surallocation accordée aux banques garantes de son augmentation de capital et de son introduction en bourse sur le nasdaq global select market
Capital/Financing Update Classification · 1% confidence The document is a press release from Innate Pharma dated October 18, 2019, announcing the full exercise of the over-allotment option granted to the underwriters of its capital increase and listing on NASDAQ. Key phrases include 'augmentation de capital' (capital increase), 'introduction en bourse sur le NASDAQ' (listing on NASDAQ), and the finalization of the offering size. This clearly relates to fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). Although it is a press release, its core subject matter is the financing event itself, not just the announcement of a report (which would be RPA or RNS).
2019-10-18 French
Innate Pharma annonce l’exercice intégral de l’option de surallocation accordée aux banques garantes de son augmentation de capital et de son introduction en bourse sur le nasdaq global select market
Capital/Financing Update Classification · 1% confidence The document is a press release dated October 18, 2019, announcing that the underwriters have exercised the full over-allotment option related to a capital increase and listing on NASDAQ. The key phrases are 'AUGMENTATION DE CAPITAL ET DE SON INTRODUCTION EN BOURSE' (Capital Increase and IPO) and the subsequent announcement about exercising the over-allotment option ('l'exercice intégral de l'option de surallocation'). This directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full 10-K, an ER (which is usually just results), or an IR (Interim Report).
2019-10-18 French
FWP (PRESS RELEASE)
Regulatory Filings
2019-10-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.